4-((氨氧基)甲基)哌啶-1-羧酸叔丁酯 | 143540-02-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-((氨氧基)甲基)哌啶-1-羧酸叔丁酯
• 英文名称: t-butyl 4-(aminooxymethyl)piperidine-1-carboxylate
• 英文别名: 4-aminooxymethyl-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-(aminooxymethyl)piperidine-1-carboxylate
• CAS: 143540-02-7
• 化学式: C₁₁H₂₂N₂O₃
• 分子量: 230.307
• InChiKey: WZWFTKHPPATADI-UHFFFAOYSA-N

物化性质

• 沸点：
  337.9±15.0 °C(Predicted)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-((氨氧基)甲基)哌啶-1-羧酸叔丁酯 在 三乙酰氧基硼氢化钠 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 22.5h， 生成
  参考文献：
  名称：

  Piperidine-based glycodendrons as protein N-glycan prosthetics

  摘要：

  The generation of homogeneously glycosylated proteins is essential for defining glycoform-specific activity and improving protein-based therapeutics. We present a novel glycodendron prosthetic which can be site-selectively appended to recombinant proteins to create 'N-glycosylated' glycoprotein mimics. Using computational modeling, we designed the dendrimer scaffold and protein attachment point to resemble the native N-glycan architecture. Three piperidine-melamine glycodendrimers were synthesized via a chemoenzymatic route and attached to human growth hormone and the F-c region of human IgG. These products represent a new class of engineered biosimilars bearing novel glycodendrimer structures. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.05.050
• 作为产物：
  描述：

  N-Boc-4-哌啶甲醇 在 一水合肼 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.0h， 生成 4-((氨氧基)甲基)哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  Piperidine-based glycodendrons as protein N-glycan prosthetics

  摘要：

  The generation of homogeneously glycosylated proteins is essential for defining glycoform-specific activity and improving protein-based therapeutics. We present a novel glycodendron prosthetic which can be site-selectively appended to recombinant proteins to create 'N-glycosylated' glycoprotein mimics. Using computational modeling, we designed the dendrimer scaffold and protein attachment point to resemble the native N-glycan architecture. Three piperidine-melamine glycodendrimers were synthesized via a chemoenzymatic route and attached to human growth hormone and the F-c region of human IgG. These products represent a new class of engineered biosimilars bearing novel glycodendrimer structures. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.05.050

文献信息

• [EN] HETEROCYCLIC OXIME COMPOUNDS<br/>[FR] COMPOSÉS D'OXIMES HÉTÉROCYCLIQUES
  申请人：NOVARTIS AG

  公开号：WO2011020861A1

  公开（公告）日：2011-02-24

  The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

  该发明涉及公式(I)的化合物及其盐，其中取代基如规范中所定义；公式(I)的化合物用于治疗人体或动物体，特别是针对c-Met酪氨酸激酶介导的疾病或症状；公式(I)的化合物用于制造治疗此类疾病的药物；包含公式(I)的化合物的药物组合物，可选地与组合伙伴一起，并且用于制备公式(I)的化合物的方法。
• [EN] OXIME DERIVATIVES AS GPR119 AGONISTS<br/>[FR] DÉRIVÉS D'OXIME FORMANT AGONISTES DU RÉCEPTEUR GPR119
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2012111995A1

  公开（公告）日：2012-08-23

  The present invention relates to oxime derivatives, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The oxime derivatives according to the present invention act as GPR119 agonists to stimulate the secretion of insulin and promote GLP-1 formation for preventing or treating type 2 diabetes, complications of diabetes, obesity, dyslipidemia or osteoporosis.

  本发明涉及肟衍生物，一种制备方法，包含该肟衍生物的药物组合物及其用途。根据本发明的肟衍生物作为GPR119激动剂，可以刺激胰岛素分泌，促进GLP-1的形成，用于预防或治疗2型糖尿病、糖尿病并发症、肥胖、血脂异常或骨质疏松症。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1741702A1

  公开（公告）日：2007-01-10

  The present invention provides a compound having p38 MAP kinase inhibitory activity. Because of having p38 MAP kinase inhibitory activity, the compounds represented by the formula (I): wherein each symbol is as defined in the description, salts thereof, N-oxides thereof, solvates thereof, or prodrugs thereof are useful in preventing and/or treating diseases that are supposedly caused or deteriorated by abnormal production of cytokines including inflammatory cytokines or chemokines, or by overresponse thereto, namely cytokine-mediated diseases such as inflammatory diseases, respiratory diseases, cardiovascular diseases and bone diseases.

  本发明提供了一种具有p38 MAP激酶抑制活性的化合物。由于具有p38 MAP激酶抑制活性，由式(I)所表示的化合物：其中每个符号如描述中所定义，其盐、N-氧化物、溶剂合物或前药在预防和/或治疗据称由细胞因子异常产生或恶化引起的疾病方面具有用处，包括炎症性细胞因子或趋化因子，或由对其过度反应引起的疾病，即细胞因子介导的疾病，如炎症性疾病、呼吸系统疾病、心血管疾病和骨疾病。
• Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof
  申请人：Fensholdt Jef

  公开号：US20070244117A1

  公开（公告）日：2007-10-18

  The invention relates to compounds of general formula I wherein D, E, F, G, W, Y, R 1 , A, R 9 , X, B, R 8 are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for treating diseases associated with deregulated angiogenesis, such as cancer.

  本发明涉及一般式I的化合物，其中D、E、F、G、W、Y、R1、A、R9、X、B、R8如本文所定义，并且其药学上可接受的盐、水合物或溶剂化物，用于治疗与异常血管生成相关的疾病，如癌症，可单独使用或与一个或多个其他药理活性化合物联合使用。
• Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof
  申请人：Nakai Hisao

  公开号：US20080081825A1

  公开（公告）日：2008-04-03

  The present invention provides a compound having p38 MAP kinase inhibitory activity. Because of having p38 MAP kinase inhibitory activity, the compounds represented by the formula (I): wherein each symbol is as defined in the description, salts thereof, N-oxides thereof, solvates thereof, or prodrugs thereof are useful in preventing and/or treating diseases that are supposedly caused or deteriorated by abnormal production of cytokines including inflammatory cytokines or chemokines, or by overresponse thereto, namely cytokine-mediated diseases such as inflammatory diseases, respiratory diseases, cardiovascular diseases and bone diseases.

  本发明提供了一种具有p38 MAP激酶抑制活性的化合物。由于具有p38 MAP激酶抑制活性，因此由式(I)表示的化合物：其中每个符号如描述中所定义的，其盐，N-氧化物，溶剂合物或前药在预防和/或治疗据称是由细胞因子异常产生或恶化引起的疾病中有用，包括炎症性细胞因子或趋化因子，或由于对其过度反应而引起的，即细胞因子介导的疾病，例如炎症性疾病，呼吸系统疾病，心血管疾病和骨骼疾病。